ISL
Australian stars Kyle Chalmers, Cate and Bronte Campbell, Ariarne Titmus and Mitch Larkin will compete in a new professional league pitting the world’s best swimmers against each other in a revolutionary club-based competition, which will be shown exclusively live in Australia on 7plus.
The International Swimming League (ISL) will hold its inaugural meet in Indianapolis next month, when eight teams – four from the United States and four from Europe – will compete over two days in a full program of events over 50m to 400m.
This will be the first of seven ISL meets across the United States and Europe in 2019, with the top four teams qualifying for the final in Las Vegas in December.
With more than $5 million in prize money at stake, and most of swimming’s current Olympic champions and world-record holders set to take part, the competition will be fierce and is bound to showcase many of the captivating rivalries expected to take centre stage at the Olympic Games Tokyo 2020.
The international big names competing include Titmus’ great rival Katie Ledecky and fellow giants of the pool Adam Peaty, Sarah Sjostrom, Ryan Murphy, Federica Pellegrini, Chad le Clos and Nathan Adrian.
The Aussie contingent taking part also includes Emma McKeon, Cam McEvoy, Emily Seebohm, Clyde Lewis, Jess Hansen and Holly Barratt, giving swimming fans a chance like never before to track the progress of our brightest Olympic Games medal hopes as Tokyo 2020 draws ever closer.
Seven’s Head of Sport Saul Shtein said: “The ISL will give swimming an established place in the annual sporting calendar and offers sports fans the chance to watch the world’s best compete regularly in an exciting new format, while this inaugural season should also provide a tantalising lead-in to Tokyo 2020. We’re thrilled to bring it to our viewers and to be adding more premium live content to 7plus.”
Kontantin Grigorishin, ISL President, declared: "We are very excited about this partnership with Seven Sport, which will allow millions of fans in Australia to experience full live coverage of International Swimming League. The heart of swimming beats in Australia and will beat even stronger from October 6 with the first ever match of ISL in Indianapolis."
Swimming fans will also be able to watch highlights of every ISL meet on 7TWO and 7plus.
In 2020, Seven is the home of the Australian swimming Olympic Games trials and Tokyo 2020.
TV Broadcast times: October 6-7 ISL – Group A: Match 1 Indianapolis, USA Sydney 5.00am LIVE on 7plus Melbourne 5.00am LIVE on 7plus Brisbane 5.00am LIVE on 7plus Adelaide 4.30am LIVE on 7plus Perth 3.00am LIVE on 7plus
October 13-14 ISL – Group A: Match 2 Naples, Italy Sydney 4.00am LIVE on 7plus Melbourne 4.00am LIVE on 7plus Brisbane 3.00am LIVE on 7plus Adelaide 3.30am LIVE on 7plus Perth 1.00am LIVE on 7plus
October 20-21 ISL – Group B: Match 1 Dallas, USA Sydney 6.00am LIVE on 7plus Melbourne 6.00am LIVE on 7plus Brisbane 5.00am LIVE on 7plus Adelaide 5.30am LIVE on 7plus Perth 3.00am LIVE on 7plus
October 27-28 ISL – Group B: Match 2 Budapest, Hungary Sydney 4.00am LIVE on 7plus Melbourne 4.00am LIVE on 7plus Brisbane 3.00am LIVE on 7plus Adelaide 3.30am LIVE on 7plus Perth 1.00am LIVE on 7plus
November 17-18 ISL – USA Derby Washington DC, USA Sydney 6.00am LIVE on 7plus Melbourne 6.00am LIVE on 7plus Brisbane 5.00am LIVE on 7plus Adelaide 5.30am LIVE on 7plus Perth 3.00am LIVE on 7plus
November 24-25 ISL – Europe Derby London, UK Sydney 4.00am LIVE on 7plus Melbourne 4.00am LIVE on 7plus Brisbane 3.00am LIVE on 7plus Adelaide 3.30am LIVE on 7plus Perth 1.00am LIVE on 7plus
December 21-22 ISL – Final Las Vegas, USA TBC
View source version on businesswire.com: https://www.businesswire.com/news/home/20190910005683/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release
Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 11:08:00 CET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 10:44:00 CET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 10:00:00 CET | Press release
Anthropic’s safety-first AI meets Allianz's dedication to customer centricity, stakeholder trust, and regulatory excellenceThree focus areas of the partnership: workforce empowerment, operations automation through agentic AI, and regulatory compliance Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE.
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 07:00:00 CET | Press release
MH002 is currently the most advanced Live Biotherapeutic Product (LBP) based on a rationally-designed combination of disease specific bacteria (microbial consortia), for the treatment of inflammatory bowel diseases (IBD) STARFISH-UC Phase 2b trial is designed to confirm MH002’s early efficacy signals and favorable safety observed in Phase 2a studies MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom